They identified SETDB1 (or SETDB1 recruited by KDM5B) as a chromatin regulator that depresses tumour-intrinsic immunogenicity and mediates immune tolerance in both mice and human tumours, and SETDB1 depletion potently boosted the efficacy of ICB in mouse models. Here, KDM5B is linked to neoplasm.